ZYMEWORKS INC (US)(ZYME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ZYME ZYMEWORKS INC (US)

Post-Mkt 01-22 18:24:54 EST

23.55

-0.40

-1.67%

盘后23.55

+0.000.00%

18:09 EST

High24.31	Low23.50	Vol590.44K
Open23.95	D1 Closing23.95	Amplitude3.38%
Mkt Cap1.76B	Tradable Cap901.95M	Total Shares74.84M
T/O14.03M	T/O Rate1.54%	Tradable Shares38.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ZYME","market":"US","secType":"STK","nameCN":"ZYMEWORKS INC (US)","latestPrice":23.55,"timestamp":1769115600000,"preClose":23.95,"halted":0,"volume":590443,"hourTrading":{"tag":"盘后","latestPrice":23.55,"preClose":23.55,"latestTime":"18:09 EST","volume":13639,"amount":320895.991536,"timestamp":1769123390048,"change":0,"changeRate":0,"amplitude":0.036093},"delay":0,"changeRate":-0.016701461377870506,"floatShares":38299500,"shares":74836534,"eps":-0.84316,"marketStatus":"Post-Mkt","change":-0.4,"latestTime":"01-22 18:24:54 EST","open":23.95,"high":24.31,"low":23.5,"amount":14025699.499448001,"amplitude":0.03382,"askPrice":24.02,"askSize":83,"bidPrice":23.25,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-0.84316,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1769130000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1493352000000,"exchange":"NASDAQ","adjPreClose":23.95,"preHourTrading":{"tag":"盘前","latestPrice":24.25,"preClose":23.95,"latestTime":"09:05 EST","volume":642,"amount":15454.891679999999,"timestamp":1769090718975,"change":0.3,"changeRate":0.012526,"amplitude":0.070021},"postHourTrading":{"tag":"盘后","latestPrice":23.55,"preClose":23.55,"latestTime":"18:09 EST","volume":13639,"amount":320895.991536,"timestamp":1769123390048,"change":0,"changeRate":0,"amplitude":0.036093},"volumeRatio":0.752715,"impliedVol":0.4847,"impliedVolPercentile":0.1952},"requestUrl":"/m/hq/s/ZYME/wiki","defaultTab":"wiki","newsList":[{"id":"2605614831","title":"Zymeworks Inc. unveils strategy focused on growing royalty portfolio and advancing novel medicines for difficult-to-treat diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2605614831","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605614831?lang=en_us&edition=fundamental","pubTime":"2026-01-21 01:29","pubTimestamp":1768930168,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. unveils strategy focused on growing royalty portfolio and advancing novel medicines for difficult-to-treat diseases. Zymeworks Inc. presented an update on its business strategy and operations at the JPM Healthcare Conference. The company highlighted its focus on expanding its royalty and asset portfolio, leveraging both asset-based pipeline partnerships and platform discovery collaborations. Key commercial partners and programs were discussed, including zanidatamab and several early-stage oncology assets such as antibody-drug conjugates and T-cell engagers. Zymeworks reported cash resources exceeding $270 million and outlined potential milestone and royalty payments from partnered products. The company stated that its current financial position is expected to fund operations beyond 2028. Additionally, Zymeworks announced a share repurchase plan and reported $103 million in revenues for 2025. You can access the full presentation through the link below.Disclaimer: This new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL9XwXVT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2603653419","title":"Zymeworks Inc. Files Initial Beneficial Ownership Statement for Mark Hollywood, EVP & Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2603653419","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603653419?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:04","pubTimestamp":1768341879,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Mark Hollywood as the beneficial owner, serving as Executive Vice President and Chief Operating Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL3Gv3Nm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2603658312","title":"Zymeworks Inc. Files Initial Statement of Beneficial Ownership for Director Brian N. Cherry","url":"https://stock-news.laohu8.com/highlight/detail?id=2603658312","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603658312?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:15","pubTimestamp":1768338941,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Brian N. Cherry as a director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDLdQLjf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Zymeworks Inc. Files Initial Statement of Beneficial Ownership for Director Brian N. Cherry","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2602241541","title":"BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners","url":"https://stock-news.laohu8.com/highlight/detail?id=2602241541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602241541?lang=en_us&edition=fundamental","pubTime":"2026-01-12 23:40","pubTimestamp":1768232404,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver minersEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL6N3YD0S4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WMT","AGCO","CRH","SHAK","ATRA","JBHT","CDE","URBN","MDLN","JILL","OMF","AFRM","ZYME","FERG","SEZL","VG","HL","QXO","AEO","JCAP","KLAR","SRRK","AWK","ALB","CAT","XYZ","SLNO","ABNB","URI","BIRK","CRWD","CMI","SCCO","SNCY","ANF","AKAM","APH","MRNA","WBD","SLM","LYRA","SYF","BAC","EPD","NEM"],"gpt_icon":1},{"id":"2602511370","title":"Zymeworks Chief Finance, Medical, Scientific Officers Leaving in Executive Reorg","url":"https://stock-news.laohu8.com/highlight/detail?id=2602511370","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602511370?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:34","pubTimestamp":1768217640,"startTime":"0","endTime":"0","summary":"Zymeworks unveiled a C-suite realignment that includes the departure of the biotechnology company's top finance and science officers.Zymeworks on Monday said the moves are aimed at aligning key leadership roles with the corporate strategy the company announced in November.Zymeworks said Leone Patterson, who joined the company as executive vice president and chief financial and business officer in September 2024, will leave the company during the first quarter.Zymeworks said its chairman and chief executive, Kenneth Galbraith, has stepped in as interim finance chief while the company conducts a search for a successor.Mark Hollywood, who joined Zymeworks in 2019 and had been executive vice president and head of technical and manufacturing operations, will now serve as executive vice president and chief operating officer, with expanded responsibilities, the company said.Zymeworks said Jeff Smith, who has been chief medical officer since January 2024, will retire at the end of the month.Sa","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Zymeworks Chief Finance, Medical, Scientific Officers Leaving in Executive Reorg","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2602519843","title":"Zymeworks Inc. unveils pipeline progress and partnership milestones in latest corporate presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2602519843","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602519843?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:04","pubTimestamp":1768215895,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. announced the completion of its $30 million share repurchase program and recognized $25.2 million in partnership milestone payments, including a $25 million regulatory milestone from Jazz following FDA approval of Ziihera for HER2-positive biliary tract cancer and a $20 million milestone from BeOne after conditional approval by the NMPA. The company also initiated a new $125 million share repurchase program and reported $2.5 million in research revenue. Recent pipeline updates include initial clinical data from the Phase 1 trial of ZW191 and the start of Phase 1 trials for both ZW191 and ZW251, while development of ZW171 has been discontinued. Zymeworks continues to emphasize partnerships, royalty, and milestone generation as central to its business strategy. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLc43PxB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2602059516","title":"Zymeworks Inc. Appoints New Executives and Board Member","url":"https://stock-news.laohu8.com/highlight/detail?id=2602059516","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602059516?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:00","pubTimestamp":1768215621,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. has announced several management changes, including the appointment of Brian Cherry to the Board of Directors and the promotion of Sabeen Mekan to Chief Medical Officer effective February 1, 2026. Mark Hollywood has been promoted to Executive Vice President and Chief Operating Officer. Five new Vice Presidents have been appointed: Charles Chen , Shrinal Inamdar , Diana Papove , Victoria Spencer , and Lingxing Zheng . Leone Patterson, Chief Financial and Business Officer, and Daniel Dex, General Counsel, will depart during the first quarter of 2026. Kenneth Galbraith has assumed the role of Acting Chief Financial Officer until a replacement is found. Additional promotions include Laura O'Connor to Senior Vice President and Chief Human Resources Officer, Bijal Desai to Senior Vice President, Finance, and Lindsey Foulkes to Senior Vice President, Corporate Development and Strategy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL9FG7Rw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4139","ZYME","BK4112","IE00BGHQF748.EUR","NDAQ","BK4585","LU2210150020.SGD","SG9999014005.SGD","BK4588","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2602519834","title":"Zymeworks Inc - Leone Patterson Will Depart From CFO Role During Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602519834","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602519834?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:00","pubTimestamp":1768215601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA13KHJD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2602516704","title":"Zymeworks Inc -  Galbraith Assumes Role of Acting CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2602516704","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602516704?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:00","pubTimestamp":1768215601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA13KHJD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2602516001","title":"Press Release: Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2602516001","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602516001?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:00","pubTimestamp":1768215600,"startTime":"0","endTime":"0","summary":"-- Dr. Sabeen Mekan to transition to Chief Medical Officer effective. February 1, 2026 and Mark Hollywood promoted to Executive Vice President. -- Five new Vice Presidents appointed, underscoring our commitment to. \"At Zymeworks, we recognize that our greatest asset is our people. Ensuring that we continue to have the right set of key skills and experience within our Board of Directors and leadership team is critical for successful execution of our current strategy and driving long-term shareholder value. Elevating talented individuals at Zymeworks recognizes their strong performance for the Company, our continued confidence in their abilities and the emphasis we place on cultivating leaders from within,\" said Kenneth Galbraith, Chair, Chief Executive Officer, and Acting Chief Financial Officer of Zymeworks.Mr. Galbraith added, \"Over the past year, we have taken deliberate steps to streamline the Board, reducing its size from twelve to nine directors, while ensuring that the collective","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4139","03160","EPM","BK4588","BK4213","BK4232","BK4022","BK4585","R","BK4604","ZYME","BK4555","BK4099"],"gpt_icon":0},{"id":"2602566165","title":"Zymeworks outlines priorities, outlook for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602566165","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602566165?lang=en_us&edition=fundamental","pubTime":"2026-01-12 08:25","pubTimestamp":1768177531,"startTime":"0","endTime":"0","summary":"Zymeworks (ZYME) outlined its strategic priorities and key milestones for 2026. Key highlights: Positive Phase 3 HERIZON-GEA-01 results for Ziihera...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zymeworks-outlines-priorities-outlook-for-2026-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zymeworks-outlines-priorities-outlook-for-2026-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2602563446","title":"Zymeworks Inc. Outlines Strategy to Drive Long-Term Value Through Royalty Growth, Strategic Acquisitions, and Internal R&D Innovation Supported by Strengthened Financial Foundation","url":"https://stock-news.laohu8.com/highlight/detail?id=2602563446","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602563446?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:05","pubTimestamp":1768172741,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. Outlines Strategy to Drive Long-Term Value Through Royalty Growth, Strategic Acquisitions, and Internal R&D Innovation Supported by Strengthened Financial Foundation. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief on January 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDL270fg0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2602563459","title":"BRIEF-Zymeworks Outlines Strategic Priorities And Outlook For 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602563459","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602563459?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:03","pubTimestamp":1768172621,"startTime":"0","endTime":"0","summary":"BRIEF-Zymeworks Outlines Strategic Priorities And Outlook For 2026Jan 11 (Reuters) - Zymeworks Inc ZYME.O:ZYMEWORKS OUTLINES STRATEGIC PRIORITIES AND OUTLOOK FOR 2026ZYMEWORKS: UP TO $440 MILLION IN M","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA4QRWPS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2602563175","title":"Zymeworks Outlines Strategic Priorities and Outlook for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602563175","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602563175?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA4QRWPS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2602438563","title":"Zymeworks Inc: Global Phase 1 Clinical Trial Investigating ZW191 in Solid Tumors Is Ongoing With Dose Optimization of ZW191 in Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2602438563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602438563?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA4QRWPS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2602356317","title":"Zymeworks: up to $440 Mln in Milestone Payments Eligible to Be Earned Related to Regulatory Approvals of Ziihera in Gea in United States, Europe, Japan, & China","url":"https://stock-news.laohu8.com/highlight/detail?id=2602356317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602356317?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA4QRWPS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2602097373","title":"Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Pacira Pharmaceuticals (PCRX) and Beta Bionics, Inc. (BBNX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602097373","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602097373?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:30","pubTimestamp":1767961839,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME – Research Report), Pacira Pharmaceu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-pacira-pharmaceuticals-pcrx-and-beta-bionics-inc-bbnx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-pacira-pharmaceuticals-pcrx-and-beta-bionics-inc-bbnx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","PCRX","BK4082","LABU","BK4007","BK4581","BK4139","BK4585","BBNX","BK4588","HCSG","XLV","ZYME","BK4137","LU0029874061.USD","XBI"],"gpt_icon":0},{"id":"2601383883","title":"Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601383883","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601383883?lang=en_us&edition=fundamental","pubTime":"2026-01-08 02:12","pubTimestamp":1767809520,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HER2-positive stomach cancer live longer, with some treatments pushing survival beyond two years.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/07/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/07/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/financing/26/01/49763409/jazz-pharmaceuticals-drug-extends-survival-past-two-years-in-advanced-stomach-cancer-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/financing/26/01/49763409/jazz-pharmaceuticals-drug-extends-survival-past-two-years-in-advanced-stomach-cancer-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4157","LU0154245673.USD","BK4532","BK4585","PFS","IE00B19Z4B17.USD","BK4139","BK4533","LU0320765992.SGD","IE00BN0W2W23.USD","IE00B7SZL793.SGD","LU0823416689.USD","JAZZ","IE00B66KJ199.SGD","AEIS","BK4195","IE00BN0W2V16.EUR","BK4211","LU0109394709.USD","BK4526","LU0154245756.USD","OS","IE0031619046.USD","BK4007","LU0889565916.HKD","LU0757428866.USD","ONC","LU1815336091.USD","IE00BN0W2T93.GBP","ZYME","BK4097"],"gpt_icon":0},{"id":"2601812408","title":"Zymeworks Announces Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2601812408","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601812408?lang=en_us&edition=fundamental","pubTime":"2026-01-07 02:34","pubTimestamp":1767724478,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera  in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra , as a first-line treatment for adults with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. The data will be presented as a late-breaking oral presentation at the 2026 ASCO Gastrointestinal Cancers Symposium on January 8, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire  on January 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL8MKtMh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","BK4112","SG9999014013.SGD","ZYME","LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","BK4139","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","LU2095319765.USD","SG9999014021.USD","NDAQ"],"gpt_icon":0},{"id":"2595748351","title":"Zymeworks Inc. Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2595748351","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595748351?lang=en_us&edition=fundamental","pubTime":"2025-12-31 06:11","pubTimestamp":1767132711,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. held its annual meeting of stockholders on December 30, 2025. During the meeting, the election of directors was approved, with Carlos Campoy, Alessandra Cesano, and Robert E. Landry elected to the board. Stockholders also ratified the appointment of KPMG LLP as the company's auditors for the year ending December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL2Y37CV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zymeworks.com","stockEarnings":[{"period":"1week","weight":-0.0272},{"period":"1month","weight":-0.1329},{"period":"3month","weight":0.3756},{"period":"6month","weight":0.7967},{"period":"1year","weight":0.676},{"period":"ytd","weight":-0.0904}],"compareEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0203},{"period":"6month","weight":0.0758},{"period":"1year","weight":0.1366},{"period":"ytd","weight":0.0051}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.021481},{"month":2,"riseRate":0.25,"avgChangeRate":-0.068196},{"month":3,"riseRate":0.375,"avgChangeRate":-0.032876},{"month":4,"riseRate":0.625,"avgChangeRate":0.039222},{"month":5,"riseRate":0.333333,"avgChangeRate":0.017913},{"month":6,"riseRate":0.555556,"avgChangeRate":-0.046141},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.030946},{"month":8,"riseRate":0.888889,"avgChangeRate":0.104131},{"month":9,"riseRate":0.444444,"avgChangeRate":0.038592},{"month":10,"riseRate":0.666667,"avgChangeRate":0.043198},{"month":11,"riseRate":0.777778,"avgChangeRate":0.135367},{"month":12,"riseRate":0.555556,"avgChangeRate":0.004939}],"exchange":"NASDAQ","name":"ZYMEWORKS INC (US)","nameEN":"ZYMEWORKS INC (US)"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ZYMEWORKS INC (US)(ZYME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ZYMEWORKS INC (US)(ZYME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ZYMEWORKS INC (US),ZYME,ZYMEWORKS INC (US)股票,ZYMEWORKS INC (US)股票老虎,ZYMEWORKS INC (US)股票老虎国际,ZYMEWORKS INC (US)行情,ZYMEWORKS INC (US)股票行情,ZYMEWORKS INC (US)股价,ZYMEWORKS INC (US)股市,ZYMEWORKS INC (US)股票价格,ZYMEWORKS INC (US)股票交易,ZYMEWORKS INC (US)股票购买,ZYMEWORKS INC (US)股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ZYMEWORKS INC (US)(ZYME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ZYMEWORKS INC (US)(ZYME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}